India–EU Trade Deal: Impact on the European Pharmaceutical Market and Consulting Opportunities for Indian Companies
India–EU Trade Deal: Impact on the European Pharmaceutical Market and Consulting Opportunities for Indian Companies riarcompany.2025@gmail.com February 2, 2026 Europe Market Entry Strategy,Uncategorized Introduction The recently concluded India–EU Free Trade Agreement (FTA)—often described as the “Mother of All Trade Deals”—marks a pivotal shift in economic and strategic relations between India and the European Union. While […]
The New Pharma Playbook (2025–2030)
The New Pharma Playbook (2025–2030) riarcompany.2025@gmail.com January 29, 2026 Industry Insights & Thought Leadership,Uncategorized The pharmaceutical industry is entering a decisive decade. Traditional growth engines—blockbuster drugs, extended patent exclusivity, and large field sales forces—are no longer sufficient in a healthcare ecosystem defined by data transparency, patient empowerment, payer scrutiny, and rapid digital innovation. From 2025 […]
SFDA’s New Digital Health Regulatory Guidance (MDS-G27): What You Must Know
SFDA’s New Digital Health Regulatory Guidance (MDS-G27): What You Must Know riarcompany.2025@gmail.com January 14, 2026 Uncategorized The Saudi Food & Drug Authority (SFDA) has recently released MDS-G27, a new regulatory guidance for Digital Health Products, marking a significant shift in how digital health solutions are classified, assessed, and regulated in the Kingdom of Saudi Arabia. […]
A Complete Guide to SFDA Product Registration in Saudi Arabia — Insights from RIAR Consulting
A Complete Guide to SFDA Product Registration in Saudi Arabia — Insights from RIAR Consulting riarcompany.2025@gmail.com January 9, 2026 SFDA Product Registration – Saudi Arabia,Uncategorized Expanding into the Kingdom of Saudi Arabia (KSA) offers immense opportunities for life science, food, health, and consumer goods companies. However, Saudi Arabia’s regulatory ecosystem is governed by one authority […]
Regulatory Bottlenecks: The Silent Multibillion-Dollar Dragon Pharma
It is a long established fact that a reader will be distracted by the readable.